Medicxi launches first USD300m late-stage life sciences fund Medicxi Growth 1
Medicxi has closed Medicxi Growth 1 (MG1), a new USD300 million fund that will focus on growth stage companies in European life sciences. With this new late stage fund, Medicxi will help fill a clear gap in Europe, where talented life sciences entrepreneurs do not have access to as much
